Unlocking the Gates: Multidrug Resistance Proteins—Mechanisms and Therapeutic Strategies
A special issue of Cells (ISSN 2073-4409).
Deadline for manuscript submissions: 30 June 2024 | Viewed by 120
Special Issue Editors
Interests: cancer therapy; anti-infective drugs; molecular mechanisms; drug synthesis; targeted therapies; bioactive heterocycle synthesis; docking and molecular modelling
Special Issues, Collections and Topics in MDPI journals
Interests: atherosclerosis; endothelial disfunction; metabolic syndromes; arterial stiffness; cardio-oncology; chemotherapy and anti-infective drugs
Interests: membrane physiology; protein transporters; oxidative stress; chemotherapy and anti-infective drugs; intracellular signaling; targeted therapy
Special Issue Information
Dear Colleagues,
Multidrug-resistant proteins (MDRs) are membrane transporters that play a crucial role in cellular defense mechanisms against various drugs. They work by actively pumping out drugs from cells, reducing their intracellular concentration and efficacy. This resistance mechanism often involves ATP-binding cassette (ABC) transporters such as P-glycoprotein, which utilize energy from ATP hydrolysis to transport drugs across cell membranes. The application fields of MDRs are diverse and span various areas of medicine and biology such cancer treatment and infectious diseases. In pharmacology, the knowledge of MDR mechanisms is valuable for drug development and designing strategies to minimize resistance. Understanding MDRs also has implications in personalized medicine, where treatment plans can be tailored based on an individual’s susceptibility to drug resistance. The purpose of this Special Issue is to present the latest knowledge regarding the mechanisms of MDRs and how the deep understanding of this phenomenon can be used to create new therapies. We welcome original and review articles covering any aspects of this topic.
Prof. Dr. Brindusa Tiperciuc
Dr. Angela Cozma
Dr. Cezar Login
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- multidrug resistance
- ABC transporters
- therapeutic resistance
- drug efflux mechanisms
- chemotherapy challenges
- targeted therapy strategies
